Email

Print

Tweet

Digg!

Del.icio.us

Company Takes Critical Step to Fast-Track Oral Insulin Product Development And Strengthen
Validation Of Its Novel Technology Platform

Dallas, TX, March 30, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.  A major focus of this program will be a first-in-man study for Access’ oral insulin product.  The study is an important step in obtaining human confirmation of the significant oral bioavailability present in Access’ Cobalamin oral insulin formulations.  The collaboration agreement comes on the heels of the Company’s recent announcement confirming significant oral bioavailability of the Cobalamin-based insulin, greater than 80% of that achieved through insulin injection, in two different animal species models.  bioRASI will utilize its Translational Clinical Development Process which has demonstrated the ability to generate high quality human proof-of-principle data very quickly and cost-effectively, particularly in the  Russian Federation.

Read more »

Email

Print

Tweet

Digg!

Del.icio.us

First Asian Approval Furthers Global Availability of Access’ FDA-Approved Product for Management of Oral Mucositis

DALLAS, TX,  March 25, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that JCOM Co., Ltd., its Korean licensee for both MuGard™and ProLindac™,  has received approval from the Korean Food and Drug Administration (KFDA) of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.  Under the agreement, JCOM is responsible for obtaining the necessary regulatory approvals for MuGard in Korea. As soon as JCOM has completed the additional steps required to import MuGard from the United States, marketing will commence.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Cobalamin Seen as Broadly Applicable for Oral Delivery of Many Large Molecule Drugs Now Administered by Injection

Dallas, TX, March 11, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies.  The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access’ Cobalamin™ Oral Drug Delivery Technology.

Read more »